Search results
Showing 46 to 60 of 370 results for hypertension
978-1-4731-3543-7 I've been diagnosed with high blood pressure. What does this mean for me? If you have high blood...
aortic valve implantation (TAVI) to treat aortic stenosis Hypertension in adults: diagnosis and management - Non-alcoholic fatty
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]
Awaiting development Reference number: GID-TA11123 Expected publication date: TBC
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
Question Pulmonary hypertension:- What are the most clinical and cost-effective treatments for pulmonary hypertension in...
Question Intracranial hypertension: What is the impact of routine monitoring of intracranial hypertension on subsequent...
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Bipolar, schizophrenia and other psychoses: annual blood pressure (IND84)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM17
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
Evidence-based recommendations on transvenous obliteration for gastric varices. This involves inserting a tube with a tiny balloon on the end into a vein in the thigh or neck. The tube is then passed into the enlarged vein in the stomach (gastric varix) and the balloon is inflated to stop blood flowing into the vein. The vein is then blocked using one of several techniques. The aim is to reduce the risk of bleeding.
View recommendations for HTG658Show all sections
Smoking: smoking status of people with long-term conditions (IND156)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126
This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
This indicator covers the percentage of patients aged 80 years or over with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is less than 145/85 mmHg if using ambulatory or home monitoring, or less than 150/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM224